EP0969852A4 - Therapie par combinaison d'agents pour le traitement du diabete et de l'obesite - Google Patents

Therapie par combinaison d'agents pour le traitement du diabete et de l'obesite

Info

Publication number
EP0969852A4
EP0969852A4 EP97946442A EP97946442A EP0969852A4 EP 0969852 A4 EP0969852 A4 EP 0969852A4 EP 97946442 A EP97946442 A EP 97946442A EP 97946442 A EP97946442 A EP 97946442A EP 0969852 A4 EP0969852 A4 EP 0969852A4
Authority
EP
European Patent Office
Prior art keywords
obesity
diabetes
agents
treatment
combination therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP97946442A
Other languages
German (de)
English (en)
Other versions
EP0969852A1 (fr
Inventor
Roy G Smith
Margaret A Cascieri
Euan Macintyre
Douglas J Macneil
John G Menke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9711042.3A external-priority patent/GB9711042D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0969852A1 publication Critical patent/EP0969852A1/fr
Publication of EP0969852A4 publication Critical patent/EP0969852A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
EP97946442A 1996-10-31 1997-10-30 Therapie par combinaison d'agents pour le traitement du diabete et de l'obesite Ceased EP0969852A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2923396P 1996-10-31 1996-10-31
US29233P 1996-10-31
GBGB9711042.3A GB9711042D0 (en) 1997-05-29 1997-05-29 Combination therapy for the treatment of diabetes and obesity
GB9711042 1997-05-30
PCT/US1997/019880 WO1998018481A1 (fr) 1996-10-31 1997-10-30 Therapie par combinaison d'agents pour le traitement du diabete et de l'obesite

Publications (2)

Publication Number Publication Date
EP0969852A1 EP0969852A1 (fr) 2000-01-12
EP0969852A4 true EP0969852A4 (fr) 2004-05-06

Family

ID=26311613

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97946442A Ceased EP0969852A4 (fr) 1996-10-31 1997-10-30 Therapie par combinaison d'agents pour le traitement du diabete et de l'obesite

Country Status (5)

Country Link
EP (1) EP0969852A4 (fr)
JP (1) JP2002516605A (fr)
AU (1) AU723879C (fr)
CA (1) CA2269660A1 (fr)
WO (1) WO1998018481A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030674A1 (fr) * 1998-11-26 2000-06-02 Ferring Bv Agents neuropeptide y-y4 utilises dans le traitement des troubles de la reproduction
EP1258253A1 (fr) * 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Nouveaux remedes et utilisation d'un agoniste beta3
FR2814678B1 (fr) † 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
US20020091114A1 (en) 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
US20060148721A1 (en) * 2003-06-06 2006-07-06 Erondu Ngozi E Combination therapy for the treatment of dyslipidemia

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016542A1 (fr) * 1994-12-02 1996-06-06 Synaptic Pharmaceutical Corporation Procedes de modification du comportement alimentaire, composes utiles dans ces procedes, et adn codant un recepteur (y5) d'un neuropeptide y/peptide yy atypique hypothalamique
US5552524A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5554621A (en) * 1995-06-07 1996-09-10 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: nitrogen heterocyclic derivatives
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
WO1997016189A1 (fr) * 1995-11-01 1997-05-09 Merck & Co., Inc. Traitement combine du diabete et de l'obesite

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635503A (en) * 1995-06-07 1997-06-03 Bristol-Myers Squibb Company Dihydropyridine npy antagonists: piperazine derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
WO1996016542A1 (fr) * 1994-12-02 1996-06-06 Synaptic Pharmaceutical Corporation Procedes de modification du comportement alimentaire, composes utiles dans ces procedes, et adn codant un recepteur (y5) d'un neuropeptide y/peptide yy atypique hypothalamique
US5552524A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5554621A (en) * 1995-06-07 1996-09-10 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: nitrogen heterocyclic derivatives
WO1997016189A1 (fr) * 1995-11-01 1997-05-09 Merck & Co., Inc. Traitement combine du diabete et de l'obesite

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9818481A1 *

Also Published As

Publication number Publication date
AU723879C (en) 2003-11-06
AU723879B2 (en) 2000-09-07
WO1998018481A1 (fr) 1998-05-07
JP2002516605A (ja) 2002-06-04
AU5160698A (en) 1998-05-22
EP0969852A1 (fr) 2000-01-12
CA2269660A1 (fr) 1998-05-07

Similar Documents

Publication Publication Date Title
EP0906310A4 (fr) BENZENESULFONAMIDES D'OXADIAZOLE EN TANT QU'AGONISTES -g(b) 3? SELECTIFS POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE
FR2742331B1 (fr) Instrument pour l'execution d'une therapie endoscopique
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
EP0721312A4 (fr) Utilisation de la therapie photodynamique dans le traitement de l'inflammation du tissu prostatique
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
FR2758253B1 (fr) Dispositif implantable pour le traitement d'un conduit corporel
FR2785521B1 (fr) Dispositif de suspension pour le traitement de prolapsus et d'incontinences urinaires
EP0888458A4 (fr) Combinaison d'inhibiteurs de la proteine kinase c et agents therapeutiques pour traiter des cancers
MA26586A1 (fr) Association pharmaceutique pour le traitement d'un dysfonctionnement sexuel et compositions la contenant
EP0959879A4 (fr) Therapie photodynamique pour le traitement de l'arthrose
MA24332A1 (fr) Utilisation de 1-hydroxy-2- pyridones pour le traitement d'infections de la peau
FR2746658B1 (fr) Valve de drainage implantable pour le traitement de l'hydrocephalie
FI973023L (fi) Liikakasvusairauksien yhdistetty terapeuttinen hoito
EP0760659A4 (fr) Application d'acides hydroxy alpha dans le traitement des vergetures
IL117695A0 (en) Pharmaceutical agents for the treatment of alzheimer's disease
DZ1988A1 (fr) Thérapie de combinaison pour le traitement de l'hiv.
FR2758465B1 (fr) Composition pour le traitement de l'amiante
FR2756183B1 (fr) Association d'huile et de peptides d'argan utile pour le traitement des troubles lies au vieillissement cutane
FR2786096B1 (fr) Composition pour la prevention et le traitement topique de la cellulite
EP0859761A4 (fr) 4-azasteroides utilises pour le traitement d'etats hyperandrogeniques
FR2718024B1 (fr) Médicament et composition pharmaceutique pour le traitement de l'inflammation.
FR2759906B1 (fr) Utilisation de milnacipran et de ses derives pour la preparation d'un medicament destine au traitement de certaines maladies psychiatriques
MA24411A1 (fr) Muteines de l'obesite
FR2728161B1 (fr) Dispositif d'orthese pour le traitement de l'hallux valgus
FR2751544B1 (fr) Composition therapeutique pour le traitement des verrues vulgaires

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990531

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20040322

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 45/06 B

Ipc: 7A 61K 38/22 B

Ipc: 7A 61K 31/445 B

Ipc: 7A 61K 31/47 B

Ipc: 7A 61K 31/44 B

Ipc: 7A 61K 31/495 B

Ipc: 7A 61K 31/55 B

Ipc: 7A 61K 38/00 A

17Q First examination report despatched

Effective date: 20050207

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20090605